The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System

Objectives To provide a map of Anatomical Therapeutic Chemical (ATC) Classification System codes to individual Rx-Risk comorbidities and to validate the Rx-Risk Comorbidity Index. Design The 46 comorbidities in the Rx-Risk Index were mapped to dispensing’s indicative of each condition using ATC codes. Prescription dispensing claims in 2014 were used to calculate the Rx-Risk. A baseline logistic regression model was fitted using age and gender as covariates. Rx-Risk was added to the base model as an (1) unweighted score, (2) weighted score and as (3) individual comorbidity categories indicating the presence or absence of each condition. The Akaike information criterion and c-statistic were used to compare the models. Setting Models were developed in the Australian Government Department of Veterans’ Affairs health claims data, and external validation was undertaken in a 10% sample of the Australian Pharmaceutical Benefits Scheme Data. Participants Subjects aged 65 years or older. Outcome measures Death within 1 year (eg, 2015). Results Compared with the base model (c-statistic 0.738, 95% CI 0.734 to 0.742), including Rx-Risk improved prediction of mortality; unweighted score 0.751, 95% CI 0.747 to 0.754, weighted score 0.786, 95% CI 0.782 to 0.789 and individual comorbidities 0.791, 95% CI 0.788 to 0.795. External validation confirmed the utility of the weighted index (c-statistic=0.833). Conclusions The updated Rx-Risk Comorbidity Score was predictive of 1-year mortality and may be useful in practice to adjust for confounding in observational studies using medication claims data.

[1]  A R Feinstein,et al.  THE PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE. , 1970, Journal of chronic diseases.

[2]  E. Roughead,et al.  Prevalence of comorbidity of chronic diseases in Australia , 2008, BMC public health.

[3]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[4]  Christine Y. Lu,et al.  Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting. , 2011, Journal of clinical epidemiology.

[5]  E. Roughead,et al.  Validity of medication‐based co‐morbidity indices in the Australian elderly population , 2009, Australian and New Zealand journal of public health.

[6]  H. Bozdogan,et al.  Akaike's Information Criterion and Recent Developments in Information Complexity. , 2000, Journal of mathematical psychology.

[7]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[8]  Peter J. Richardson,et al.  Adapting the Rx-Risk-V for Mortality Prediction in Outpatient Populations , 2006, Medical care.

[9]  Gregory E. Simon,et al.  A Chronic Disease Score with Empirically Derived Weights , 1995, Medical care.

[10]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[11]  C. Steiner,et al.  Comorbidity measures for use with administrative data. , 1998, Medical care.

[12]  E H Wagner,et al.  A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.

[13]  Anne E Sales,et al.  Predicting Costs of Care Using a Pharmacy-Based Measure Risk Adjustment in a Veteran Population , 2003, Medical care.

[14]  William D. Marder,et al.  Multiple Chronic Conditions: Prevalence, Health Consequences, and Implications for Quality, Care Management, and Costs , 2007, Journal of General Internal Medicine.

[15]  Anne E Sales,et al.  Construction and Characteristics of the RxRisk-V: A VA-Adapted Pharmacy-Based Case-mix Instrument , 2003, Medical care.

[16]  P. Davies,et al.  Knowledge brokerage and research utilisation: a discussion document prepared for the Australian Government Department of Health and Ageing , 2017 .

[17]  E. Roughead,et al.  Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts. , 2010, Diabetes research and clinical practice.